Akute tubulointerstitielle Nephritis bei HIV-Erkrankung

Möddel, Michael; Pfammatter, Rahel; Varga, Zsuzsanna; Keusch, G

doi:10.1024/0369-8394.95.23.949

Cited by 4 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Not much data are available on side effects and kidney pathology arising under atazanavir therapy [20]. Only two patients with acute interstitial nephritis have been reported in the literature so far, one of them is a patient in our study [1,17]. According to our knowledge, no systematic clinicopathological case series has analyzed the incidence of acute interstitial nephritis under atazanavir therapy up to now.…”

Section: Discussionmentioning

confidence: 49%

“…This protease inhibitor was released in 2004 [1,20]. So far, two cases of acute interstitial nephritis under atazanavir therapy have been published in the literature [1,17]. Consequently, we investigated the frequency of kidney pathology, especially the occurrence of acute interstitial nephritis in kidney biopsies of 30 HIVpositive patients, with special emphasis on atazanavir therapy.…”

Section: Introductionmentioning

confidence: 96%

See 1 more Smart Citation

Acute interstitial nephritis of HIV-positive patients under atazanavir and tenofovir therapy in a retrospective analysis of kidney biopsies

et al. 2007

View full text Add to dashboard Cite

We performed a retrospective analysis on kidney biopsies of 30 human immunodeficiency virus (HIV)-positive patients. Twenty-two of them received highly active antiretroviral therapy (HAART). Tenofovir containing HAART together with atazanavir, a new protease inhibitor, was administered to three patients. All of them developed acute renal failure. The kidney biopsies of these patients showed an acute interstitial nephritis or a chronic interstitial nephritis with an acute component. Withdrawal of atazanavir and tenofovir resulted in recovery of renal function in all three patients. Acute interstitial nephritis was observed only in 1 of 19 patients without atazanavir or tenofovir treatment. We conclude that acute interstitial nephritis and consecutive acute renal failure is a relevant side effect of atazanavir and tenofovir therapy in HIV-positive patients.

show abstract

Section: Discussionmentioning

confidence: 49%

Section: Introductionmentioning

confidence: 96%

Acute interstitial nephritis of HIV-positive patients under atazanavir and tenofovir therapy in a retrospective analysis of kidney biopsies

et al. 2007

View full text Add to dashboard Cite

show abstract

“…Acute renal failure due to insterstitial nephritis has been reported in patients receiving atazanavir [81–83]. Nephrolithiasis also appears to be associated with atazanavir use [84,85] and may result in acute renal failure [86].…”

Section: Safety and Tolerabilitymentioning

confidence: 99%

Atazanavir: its role in HIV treatment

Wood¹

2008

Expert Review of Anti-infective Therapy

View full text Add to dashboard Cite

Azatanavir is a protease inhibitor (PI) approved for the treatment of HIV-1 infection. Atazanavir is a substrate and inhibitor of cytochrome P450 isozyme 3A and an inhibitor and inducer of P-glycoprotein. It has similar virologic efficacy as efavirenz and ritonavir-boosted lopinavir in antiretroviral-naive individuals. Its impact on lipids is less than other PIs and it is suitable for those in whom hyperlipidemia is undesirable. Ritonavir boosting of atazanavir enhances the bioavailability of atazanavir but may result in some elevation of lipids and is recommended for treatment-experienced patients and those receiving efavirenz or tenofovir. Ritonavir-boosted atazanavir has similar antiviral activity as ritonavir-boosted lopinavir in both antiretroviral therapy-naive and -experienced patients. Atazanavir causes unconjugated bilirubinemia in over 40% of patients but results in less than 2% discontinuations. Atazanavir is licensed for once-daily use and atazanavir/ritonavir competes with lopinavir/ritonavir as the most commonly prescribed PI.

show abstract